Search All UT System Experts

Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors

Alain C. Mita, Lisa A. Hammond, Peter L. Bonate, Geoffrey Weiss, Heather McCreery, Samira Syed, Mitchell Garrison, Quincy S C Chu, Johann S. DeBono, Christopher B. Jones, Steve Weitman, Eric K. Rowinsky

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences